,outcome,arm 1,arm 2
0,intervention,"Capecitabine/docetaxel, docetaxel","., docetaxel"
0,"objective tumor response rate, efficacy in time to disease progression, overall survival","14.5, 42 %, 6.1","11.5 months, 30 %, 4.2 months"
